Levamisole in aphthous stomatitis: evaluation of three regimens

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Recurrent aphthous stomatitis (RAS) is a common condition causing significant discomfort.
• Existing treatments for RAS have varying efficacy and side effect profiles.

Purpose of the Study:

• To evaluate the effectiveness of levamisole in treating recurrent aphthous stomatitis (RAS).
• To determine an optimal treatment regimen for levamisole in RAS patients.

Main Methods:

• A total of 124 patients with a history of RAS participated in three studies.
• Double-blind, placebo-controlled trials and an open-label trial were conducted.
• Levamisole was administered either on a fixed schedule (150 mg/day for three consecutive days every fortnight) or on an as-needed basis during RAS episodes.

Main Results:

• Levamisole treatment led to gradual and significant improvement in RAS signs and symptoms compared to placebo.
• The active drug showed significant intergroup differences favoring levamisole.
• Earlier improvement was observed in the open-label study where levamisole was given only when episodes occurred.

Conclusions:

• Levamisole demonstrates efficacy in managing recurrent aphthous stomatitis.
• The findings suggest levamisole may have a role in preventing new episodes of RAS.
• Levamisole was well-tolerated by patients throughout the studies.